Wnt-C59 (C59) Clinical Trials

Size	Price	Qty
5mg	USD 247
25mg	USD 570

Clinical Trials

A completed clinical trial associated with this compound evaluated therapeutic outcomes in individuals affected by rheumatoid arthritis. Sponsored by the industry sponsor Hoffmann-La Roche, this comparative observational study had no assigned formal phase and assessed patient responses to specific treatment protocols. Overall, the clinical landscape for this compound consists of observational research within the domain of autoimmune inflammatory conditions.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02679001	Completed	Rheumatoid Arthritis	Hoffmann-La Roche	2016-03-24	--

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Wnt-C59 (C59) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Wnt-C59 potently inhibits the O-acyltransferase Porcupine (PORCN), which blocks Wnt protein palmitoylation and prevents Wnt3A-mediated downstream activation of TCF transcriptional responses. This targeted disruption of canonical Wnt signaling suppresses aberrant cellular proliferation and pathway-driven inflammatory signaling, which is clinically relevant to hyperproliferative and autoimmune conditions such as rheumatoid arthritis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).